Blog
Archives: FAQs
-
How does MPEP 2111.04 affect the interpretation of method claims with contingent limitations?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How does MPEP 2111.04 treat the phrase “configured to” in patent claims?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How does MPEP 2106.05(e) distinguish between meaningful and insignificant limitations?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How can a protestor monitor the progress of an application they have protested?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
Can original patent drawings be modified during reexamination?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What are the accepted symbols for modified nucleotides in sequence listings?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What is a “Modified Nucleotide” according to MPEP 2412.03(e)?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How does the definition of “Modified Nucleotide” in MPEP 2412.03(e) affect patent applications?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What are the rules for representing modified amino acids in WIPO ST.25 sequence listings?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How are modified amino acids represented in sequence listings?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
Thirty minutes. Chief IP Officer on retainer — and the capital option behind it.
If what you need is something else, we’ll tell you on the same call.